Clinical Trials Logo

Malignant Neoplasm clinical trials

View clinical trials related to Malignant Neoplasm.

Filter by:

NCT ID: NCT00091117 Completed - Malignant Neoplasm Clinical Trials

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Start date: July 2004
Phase: Phase 1
Study type: Interventional

Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. This phase I trial is studying the side effects and best dose of bortezomib in treating patients with advanced cancer and liver dysfunction.

NCT ID: NCT00060372 Completed - Clinical trials for Stage IV Breast Cancer

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Start date: April 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

NCT ID: NCT00026169 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure

Start date: September 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure. Imatinib mesylate may stop the growth of cancer cells by stopping the enzyme necessary for cancer cell growth. Kidney failure may delay the elimination of imatinib mesylate from the body, which may lead to longer drug exposure and increase toxic side effects